Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Comparing the safety of direct oral anticoagulants vs. low-molecular-weight heparin in patients with thrombocytopenia and venous thromboembolism

View through CrossRef
Abstract Introduction: Balancing the safety and efficacy of anticoagulation (AC) for venous thromboembolism (VTE) among patients with thrombocytopenia (TCP) is challenging as there are limited data on outcomes. As a general practice, patients with VTE and platelet count (PC) > 50,000, a full dose of AC is considered safe. In 2018 International Society of Thrombosis and Hemostasis (ISTH) Standardization Committee updated guidance statement on the management of AC in Cancer-associated Thrombosis and TCP. ISTH recommended full dose low molecular weight heparin (LMWH)/unfractionated heparin with transfusion support or dose-reduced LMWH based on risk of thrombus progression for patients with PC between 25,000 and 50,000. Despite increasing clinical use of DOAC (direct oral anticoagulants) in patients with VTE, including patients with TCP, the safety of DOAC in TCP is unclear, and additional data is needed to support clinical decision making. Methods: In this retrospective cohort study conducted at Emory Healthcare from 2017 to 2022, patients ≥18 years with the following ICD-10 diagnosis codes: I82(other venous embolism and thrombosis), I26(Pulmonary embolism), I81(portal vein thrombosis), and PC <100,000 were identified from electronic health records(EHR).The primary outcome of interest is a composite of either major bleeding (MB), clinically-relevant non-major bleeding (CRNMB), minor bleeding, recurrent VTE, or VTE progression. MB and CRNMB were defined by ISTH criteria. Patients were followed from their index date (defined as the first simultaneous occurrence of VTE, PC <100,000, and AC use either with DOAC or LMWH) until their PC improved to at least 100,000 for 7 or more days; they stopped AC; they experienced one of the composite outcome events, or until the study end (6 months after index date). This study was approved by the Institutional Review Board. Descriptive statistics were calculated for each demographic and clinical covariate by treatment group. Systematic differences between treatment groups were examined with Pearson-chi square test, Fisher's exact test, two-sample t-tests and Kruskal-Wallis tests. Results: Three hundred EHR were reviewed, 69 patients met inclusion criteria, and 231 were excluded. DOAC was prescribed to 47 patients (68.1%) and LMWH to 22 patients (31.9%). The mean age was 60 years (SD=12.8). There were 31 males (46.3%) and 36 females (53.7%), 36 participants were White (53.7%), 26 Black (38.8%), and 4 Asian (6.0%). Though the number of comorbidities was slightly higher among patients on DOAC (mean=2.2, SD=1.1) compared to LMWH (mean=1.3, SD=0.6), none of the differences met the statistical significance threshold. LMWH was used more commonly among cancer patients (86.4% vs 63.8%) and DOAC among hypertensive patients (46.8% vs. 22.7%). Among patients with an adverse outcome, no significant differences were observed in the prevalence of either comorbidity occurrence or by treatment type. A composite outcome was observed in 17 (25%) patients. While the proportion of events was higher among patients receiving DOAC compared to LMWH (14, 29.8% vs. 3, 13.6%), the difference was not statistically significant (p 0.154). Composite outcomes in the DOAC cohort were 8 MB (57.1%), 3 CRNMB (21.4%), 1 minor bleeding (7.1%), 1 VTE progression and 1 multiple events (MB and VTE). The only reported outcome in LMWH cohort was CRNMB (3, 100%). In the DOAC cohort, 11 patients received Apixaban and 3 received Rivaroxaban. Median PC on the day of bleeding in the DOAC cohort was 80,000. Median PC in the LMWH cohort on the outcome days couldn't be accurately determined because of missing data, but PC was <100,000. There was no anti-platelet use in any of the patients with outcomes, except one patient with both MB and VTE. There was no difference in bleeding outcomes based on DOAC doses. Conclusion: Based on our preliminary data from a single-institutional cohort study, composite outcomes were higher among patients on DOAC compared to LMWH (29.8% vs. 13.6%), but the difference did not meet statistical significance. LMWH cohort notably only had 3 CRNMB without any MB or new VTE. Despite increasing clinical use of DOAC, our study provides a signal for a better safety profile for LMWH in patients with TCP. We will continue to collect data to increase the sample size and evaluate whether any subgroup of patients with TCP and VTE will have a safety profile at lower doses of DOAC comparable to LMWH.
Title: Comparing the safety of direct oral anticoagulants vs. low-molecular-weight heparin in patients with thrombocytopenia and venous thromboembolism
Description:
Abstract Introduction: Balancing the safety and efficacy of anticoagulation (AC) for venous thromboembolism (VTE) among patients with thrombocytopenia (TCP) is challenging as there are limited data on outcomes.
As a general practice, patients with VTE and platelet count (PC) > 50,000, a full dose of AC is considered safe.
In 2018 International Society of Thrombosis and Hemostasis (ISTH) Standardization Committee updated guidance statement on the management of AC in Cancer-associated Thrombosis and TCP.
ISTH recommended full dose low molecular weight heparin (LMWH)/unfractionated heparin with transfusion support or dose-reduced LMWH based on risk of thrombus progression for patients with PC between 25,000 and 50,000.
Despite increasing clinical use of DOAC (direct oral anticoagulants) in patients with VTE, including patients with TCP, the safety of DOAC in TCP is unclear, and additional data is needed to support clinical decision making.
Methods: In this retrospective cohort study conducted at Emory Healthcare from 2017 to 2022, patients ≥18 years with the following ICD-10 diagnosis codes: I82(other venous embolism and thrombosis), I26(Pulmonary embolism), I81(portal vein thrombosis), and PC <100,000 were identified from electronic health records(EHR).
The primary outcome of interest is a composite of either major bleeding (MB), clinically-relevant non-major bleeding (CRNMB), minor bleeding, recurrent VTE, or VTE progression.
MB and CRNMB were defined by ISTH criteria.
Patients were followed from their index date (defined as the first simultaneous occurrence of VTE, PC <100,000, and AC use either with DOAC or LMWH) until their PC improved to at least 100,000 for 7 or more days; they stopped AC; they experienced one of the composite outcome events, or until the study end (6 months after index date).
This study was approved by the Institutional Review Board.
Descriptive statistics were calculated for each demographic and clinical covariate by treatment group.
Systematic differences between treatment groups were examined with Pearson-chi square test, Fisher's exact test, two-sample t-tests and Kruskal-Wallis tests.
Results: Three hundred EHR were reviewed, 69 patients met inclusion criteria, and 231 were excluded.
DOAC was prescribed to 47 patients (68.
1%) and LMWH to 22 patients (31.
9%).
The mean age was 60 years (SD=12.
8).
There were 31 males (46.
3%) and 36 females (53.
7%), 36 participants were White (53.
7%), 26 Black (38.
8%), and 4 Asian (6.
0%).
Though the number of comorbidities was slightly higher among patients on DOAC (mean=2.
2, SD=1.
1) compared to LMWH (mean=1.
3, SD=0.
6), none of the differences met the statistical significance threshold.
LMWH was used more commonly among cancer patients (86.
4% vs 63.
8%) and DOAC among hypertensive patients (46.
8% vs.
22.
7%).
Among patients with an adverse outcome, no significant differences were observed in the prevalence of either comorbidity occurrence or by treatment type.
A composite outcome was observed in 17 (25%) patients.
While the proportion of events was higher among patients receiving DOAC compared to LMWH (14, 29.
8% vs.
3, 13.
6%), the difference was not statistically significant (p 0.
154).
Composite outcomes in the DOAC cohort were 8 MB (57.
1%), 3 CRNMB (21.
4%), 1 minor bleeding (7.
1%), 1 VTE progression and 1 multiple events (MB and VTE).
The only reported outcome in LMWH cohort was CRNMB (3, 100%).
In the DOAC cohort, 11 patients received Apixaban and 3 received Rivaroxaban.
Median PC on the day of bleeding in the DOAC cohort was 80,000.
Median PC in the LMWH cohort on the outcome days couldn't be accurately determined because of missing data, but PC was <100,000.
There was no anti-platelet use in any of the patients with outcomes, except one patient with both MB and VTE.
There was no difference in bleeding outcomes based on DOAC doses.
Conclusion: Based on our preliminary data from a single-institutional cohort study, composite outcomes were higher among patients on DOAC compared to LMWH (29.
8% vs.
13.
6%), but the difference did not meet statistical significance.
LMWH cohort notably only had 3 CRNMB without any MB or new VTE.
Despite increasing clinical use of DOAC, our study provides a signal for a better safety profile for LMWH in patients with TCP.
We will continue to collect data to increase the sample size and evaluate whether any subgroup of patients with TCP and VTE will have a safety profile at lower doses of DOAC comparable to LMWH.

Related Results

Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Abstract Introduction Among the most frequently used anticoagulants in hematological testing are tetra-acetic acid (EDTA), sodium citrate, and sodium heparin. However, there is a n...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Case Report: Maggots' Infestation As a Predisposing Condition for Heparin-Induced Thrombocytopenia, a Newest Entity
Case Report: Maggots' Infestation As a Predisposing Condition for Heparin-Induced Thrombocytopenia, a Newest Entity
Abstract Introduction Thromobocytopenia is a well-recognized complication of heparin with risk of venous or arterial thrombosis. Heparin induced throm...
Direct costs for treatment of venous thromboembolism complication 90-day after surgery
Direct costs for treatment of venous thromboembolism complication 90-day after surgery
Study object: Describe the direct treatment costs due to venous thromboembolism complications 90 days after surgery by using national health insurance reimbursement database. Patie...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Abstract The immune response to platelet factor 4 (PF4)/heparin complexes is a frequent iatrogenic complication of heparin therapy associated with development of hep...
Use of recombinant hirudin as antithrombotic treatment in patients with heparin‐induced thrombocytopenia
Use of recombinant hirudin as antithrombotic treatment in patients with heparin‐induced thrombocytopenia
AbstractHeparin‐induced thrombocytopenia is a rare but severe complication of heparin therapy that can result in severe venous or arterial thromboembolic events and whose treatment...
Tracing Hematological Shifts in Pregnancy: How Anemia and Thrombocytopenia Evolve Across Trimesters
Tracing Hematological Shifts in Pregnancy: How Anemia and Thrombocytopenia Evolve Across Trimesters
Abstract Introduction Given pregnancy's significant impact on hematological parameters, monitoring these changes across trimesters is crucial. This study aims to evaluate hematolog...

Back to Top